Everyone’s talking about Ozempic. Your coworker lost 40 pounds. Your social media feed is full of before-and-after photos. Half the telehealth companies in your inbox are offering semaglutide prescriptions with a free consultation. But here’s what you’ve probably noticed: every piece of information you find is coming from someone who profits when you start a prescription. The telehealth company blog, the influencer with a discount code, the pharmacy running ads — they all have great content, and they all have a financial interest in your decision. You’re here because you want an honest, independent assessment of what semaglutide does, what it doesn’t do, what it costs, and what nobody’s telling you about the regulatory landscape in 2026.
Semaglutide
GLP-1 Receptor Agonist
Also known as: Wegovy (weight management), Ozempic (diabetes), Rybelsus (oral)
Evidence Summary
- Strongest evidence for:
- Weight loss (14.9% average in STEP 1 trial, up to 21% at higher doses), cardiovascular protection (20% reduction in major events in SELECT trial), type 2 diabetes
- Promising but early:
- Kidney disease (FLOW trial), liver disease (MASH/NASH), addiction, Alzheimer’s
- Mostly anecdotal:
- N/A — this is one of the most rigorously studied compounds in modern medicine
- Key limitation:
- Not the evidence — it’s access. Brand-name cost is $935–$1,349/month with no generics until early 2030s.
What It Is
Semaglutide is a synthetic GLP-1 receptor agonist. Your gut naturally produces GLP-1 after eating — it tells your brain you’re full, slows stomach emptying and regulates blood sugar. Semaglutide mimics this but lasts a week instead of minutes, which is why it’s dosed weekly. Manufactured by Novo Nordisk as Wegovy (weight), Ozempic (diabetes) and Rybelsus (oral). This is a fully FDA-approved pharmaceutical, not a compounded peptide.
What the Research Says
Weight Loss
T1: Strong EvidenceSTEP 1 trial (1,961 participants) showed 14.9% weight reduction vs 2.4% placebo. STEP UP trial at higher 7.2mg dose achieved ~21% loss. Oral 25mg formulation achieved 16.6% loss.
Cardiovascular
T1: Strong EvidenceSELECT trial (17,604 participants, 41 countries) showed 20% reduction in heart attack, stroke and cardiovascular death.
Type 2 Diabetes
T1: Strong EvidenceExtensive SUSTAIN and PIONEER trial programs with significant HbA1c reduction.
Emerging Indications
T2: Emerging EvidenceActive investigation in kidney disease, liver disease, addiction, Alzheimer’s and sleep apnea.
Typical Protocol
| Route | Weekly subcutaneous injection or daily oral tablet |
| Dosage | Injectable starts at 0.25mg weekly, escalates to 2.4mg maintenance |
| Frequency | Once weekly (injectable) or daily (oral) |
| Time to Effect | Weight loss typically begins within 4–8 weeks |
| Note | Prescribed by licensed physicians with standardized dose escalation. Not appropriate for self-dosing. |
Protocols vary by individual. Always follow your prescribing provider's instructions.
Risks & Side Effects
- GI effects (nausea, vomiting, diarrhea, constipation) — most common, usually during escalation.
- Muscle loss — research shows meaningful lean mass reduction, especially in women and older adults. Resistance training and protein intake are important.
- Pancreatitis — rare but reported.
- Thyroid concerns — boxed warning, contraindicated with medullary thyroid carcinoma history or MEN 2.
- Gallbladder issues — increased gallstone risk.
- Weight regain — STEP 4 trial showed significant regain after discontinuation.
Who Should Not Consider Semaglutide
If you have a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2): This is a boxed warning — the FDA’s most serious category. Animal studies showed thyroid C-cell tumors. This is not a theoretical hedge. It is a hard contraindication.
If you have a history of pancreatitis: Rare cases of acute pancreatitis have been reported in clinical trials and post-marketing surveillance. If you’ve had pancreatitis before, the risk-benefit calculation changes significantly. Your provider needs to weigh this explicitly.
If you have a history of gallbladder disease: Semaglutide increases the risk of gallstones and cholecystitis, likely driven by rapid weight loss. If you’ve had gallbladder issues — or have already had your gallbladder removed — discuss this with your provider before starting.
If you are pregnant, planning to become pregnant, or breastfeeding: Semaglutide is contraindicated in pregnancy. The FDA recommends discontinuing at least 2 months before a planned pregnancy due to the drug’s long half-life. There is no safety data in breastfeeding.
If you have a history of eating disorders: Semaglutide dramatically reduces appetite and can alter your relationship with food. For someone with a history of anorexia or restrictive eating patterns, this appetite suppression can reinforce disordered behaviors. A provider who understands both metabolic health and eating disorder history should be involved — not just someone who will write the prescription.
If you have diabetic retinopathy: The SUSTAIN-6 trial showed an increased rate of retinopathy complications in patients with type 2 diabetes using semaglutide. If you have existing diabetic retinopathy, your ophthalmologist and prescriber both need to be aware.
If you are using compounded semaglutide from any source: As of 2026, there is no legitimate compounded semaglutide available. The FDA has issued dozens of warning letters to compounders and telehealth companies. If your semaglutide is not brand-name Ozempic, Wegovy, or Rybelsus from a licensed retail pharmacy, you are taking an unregulated product with no quality assurance. This isn’t a gray area — it’s a red flag.
If your BMI doesn’t meet prescribing criteria and you’re seeking it for cosmetic weight loss: Semaglutide is FDA-approved for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related comorbidity. Using it below these thresholds means you’re outside the studied population, your insurance won’t cover it, and the risk-benefit ratio hasn’t been established for your situation. The muscle loss concern is especially relevant for people who are not clinically overweight.
The general principle: Semaglutide is a powerful drug with a strong evidence base — and a real side effect profile. The fact that it works well is not a reason to skip the screening conversation. A good provider will evaluate your thyroid history, cancer history, gallbladder status, mental health history, and reproductive plans before prescribing. If they don’t ask, you should.
Legal & Access Status
Semaglutide is FDA-approved and available through standard prescriptions at licensed pharmacies. As of April 2026, broad compounding is effectively prohibited. The FDA removed semaglutide from its drug shortage list in February 2025 and enforcement discretion has ended. On April 1, 2026, the FDA issued further clarification and confirmed DOJ involvement in enforcement. The only remaining pathway for compounded semaglutide is a narrow patient-specific exception under 503A when a prescriber documents the FDA-approved product cannot be used for that specific patient. Brand-name Wegovy costs approximately $1,349/month and Ozempic $935/month, with no generics expected until early 2030s.
Before You Start: Get Baseline Labs
We recommend baseline lab work before starting any peptide protocol so you and your provider can track changes. Key markers include IGF-1, fasting glucose, CBC, CMP and a thyroid panel.
Ask your provider about ordering these labs, or search for direct-to-consumer lab testing services in your area.
Lab recommendations are the same regardless of which service you use. See how we make money.
Questions for Your Provider
- 1Am I a good candidate based on my BMI, health history and goals?
- 2Which formulation — injectable or oral? What’s the rationale?
- 3What’s your plan for managing GI side effects during dose escalation?
- 4How will we protect against muscle loss?
- 5What does long-term maintenance look like? What if I stop?
- 6What is the total monthly cost, and does my insurance cover it?
- 7Are you prescribing FDA-approved semaglutide? If compounded, what’s the documented clinical justification?
Find a Provider
We’re finalizing our vetted provider list. Subscribe to be notified when provider recommendations go live.
When provider links go live, we’ll disclose all affiliate relationships here. See how we make money.
Stay ahead of the FDA.
Regulatory updates as developments happen. New compound profiles weekly. No spam. No sales pitches.